Maastricht University Medical Center
Maastricht, Limburg, Netherlands
NCT Number: NCT06395051
Disturbances in brain insulin-sensitivity are not only observed in obesity and type 2 diabetes (T2D), but also during brain aging and in dementia. Ketone monoester supplements may improve brain insulin-sensitivity, which can be quantified by measuring the gray-matter cerebral blood flow (CBF) response to intranasally administered insulin. We hypothesize that acute ketone monoester supplementation increases (regional) brain vascular function and insulin-sensitivity thereby improving cognitive performance and appetite control. The primary objective is to evaluate in older men the acute effect of ketone monoester supplementation on (regional) brain vascular function and insulin-sensitivity, as quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labelling (ASL). The CBF response to intranasal insulin is a robust and sensitive physiological marker of brain insulin-sensitivity. Secondary objectives are to investigate effects on cognitive performance as assessed with a neuropsychological test battery, and appetite control as quantified by functional MRI (fMRI) with visual food cues.
Looking for future studies?
Notify Me60 year–75 year
Male
Interventional
Not applicable
Maastricht, Limburg, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ketone monoester supplement (395 mg/kg body mass)
The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
Time frame: Change from placebo intervention at 30 minutes after supplement intake
Cerebral blood flow as quantified non-invasively by the MRI perfusion method Arterial Spin Labeling (ASL)
Time frame: Change from placebo intervention at 60 minutes after supplement intake
Cerebral blood flow measurements before and after a nasal insulin spray as quantified non-invasively by the MRI perfusion method Arterial Spin Labeling (ASL)
Time frame: Change from placebo intervention at 40 minutes after supplement intake
Blood oxygenation level-dependent (BOLD)-functional MRI (fMRI) response to food cues
Time frame: Change from placebo intervention at 120 minutes after supplement intake
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Time frame: Change from placebo intervention at 120 minutes after supplement intake
Transcranial Doppler (TCD) ultrasound will be used to assess the velocity of blood flow through the middle cerebral artery (MCA)
Time frame: Change from placebo intervention at 90 minutes after supplement intake
Office blood pressure and heart rate
Time frame: During 120 minutes following supplement intake
Circulating beta-hydroxybutyrate concentrations
Time frame: During 120 minutes following supplement intake
Circulating glucose and insulin concentrations
Time frame: During 120 minutes following supplement intake
Circulating high-sensitive C-reactive protein concentrations
Time frame: During 120 minutes following supplement intake
Circulating ghrelin concentrations
Time frame: During 120 minutes following supplement intake
Visual analogue scale (VAS) questionnaires
Time frame: Before supplement intake
Weight, length, waist and hip circumference
Time frame: Once 120 minutes following supplement intake
Food Frequency Questionnaire to assess food intake over the past month
Maastricht University Medical Center
Other
Acute Effects of Ketone Monoester Supplementation on Brain Function in Older Men with Overweight
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07355309
Appetite Control, Brain Insulin Sensitivity
Maastricht, Limburg, Netherlands
View Trial DetailsNCT05724654
Brain Insulin Sensitivity, Brain Vascular Function
Maastricht, Limburg, Netherlands
View Trial DetailsNCT07422220
Abdominal Obesity, Body Weight
Maastricht, Limburg, Netherlands
View Trial DetailsNCT07057245
Brain Insulin Sensitivity, Brain Vascular Function
Maastricht, Limburg, Netherlands
View Trial Details